Clinical TrialMay 12, 2026, 04:02 PM
Inhibikase Enrolls First Patient in Phase 3 IMPROVE-PAH Study
AI Summary
Inhibikase Therapeutics announced significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, including the enrollment of the first patient and regulatory approvals in 16 countries, leveraging the new European Medicines Agency FAST-EU initiative. The company also submitted an Orphan Drug Designation application to the US FDA for IKT-001 for Pulmonary Arterial Hypertension. For the first quarter ended March 31, 2026, Inhibikase reported a net loss of $16.4 million, or $0.10 per share, and held $170.4 million in cash, cash equivalents, and marketable securities.
Key Highlights
- First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001.
- Received regulatory approvals for IMPROVE-PAH in 16 countries, including 12 EU nations.
- Submitted Orphan Drug Designation application to US FDA for IKT-001 in PAH.
- Cash, cash equivalents, and marketable securities totaled $170.4 million as of March 31, 2026.
- Reported Q1 2026 net loss of $16.4 million, or $0.10 per share.
- Q1 2026 R&D expenses were $10.8 million, compared to $10.5 million in Q1 2025.
- Q1 2026 SG&A expenses were $7.4 million, compared to $5.2 million in Q1 2025.